# Phase 7 — Dry-Run Execution Report

**Date:** 2026-06-08
**Project:** VasoSeal Pro X (Class IIb Vascular Closure Device — synthetic representative)
**Output:** `BIGDP2026_6/phase7_dry_run_output/`

---

## 1. Test Suite

**Command:** `.venv/bin/python3 -m pytest backend/.../tests/ -q`
**Result:** 500 passed, 0 failed ✅

---

## 2. Dry-Run Execution

**Script:** `BIGDP2026_6/phase7_dry_run_output/phase7_dry_run.py`
**State:** Realistic Class IIb device with 4 claims (1 marketing-overreach), 4 evidence sources, 2 endpoints
**Execution time:** < 1 second

### Pipeline Steps Executed

| Step | Node | Output | Status |
|:---|:---|:---|:---:|
| 1 | `_node_build_reasoning_ledger` | `CER_REASONING_LEDGER.json` (4 claims) | ✅ |
| 2 | `_node_build_ifu_evolution_ledger` | `IFU_CLAIM_EVOLUTION_LEDGER.json` (4 claims) | ✅ |
| 3 | `_node_build_benchmark_trace` | `BENCHMARK_DERIVATION_TRACE.json` (2 endpoints) | ✅ |
| 4 | `evaluate_pre_writer_readiness_gate` | `G46_REPORT.json` (13 conditions) | ✅ |
| 5 | Package assembly | `CER_INPUT_PACKAGE.json` | ✅ |
| 6 | `validate_package()` | `PACKAGE_VALIDATION_REPORT.txt` | ✅ |

---

## 3. Output Files

| File | Size | Content |
|:---|:---:|:---|
| `CER_REASONING_LEDGER.json` | 4.8 KB | 4 claims with classification, support type, conclusion strength, gap disposition |
| `IFU_CLAIM_EVOLUTION_LEDGER.json` | 9.7 KB | 4 claims through 5-stage evolution, marketing flags |
| `BENCHMARK_DERIVATION_TRACE.json` | 4.9 KB | 2 endpoints with acceptability rationale, confidence, directness |
| `G46_REPORT.json` | 7.0 KB | 13 conditions evaluated, 0 silent PASS |
| `CER_INPUT_PACKAGE.json` | 22.9 KB | Full export package with all 3 ledgers embedded |
| `PACKAGE_VALIDATION_REPORT.txt` | 42 B | "VALIDATION PASSED" |
| `EXPERT_LOGIC_CHECKS.txt` | 80 B | Marketing flagged: 1; Endpoints with rationale: 2/2 |

---

## 4. G46 Writer Release Board

| Condition | Status | Notes |
|:---|:---:|:---|
| identity | PASS | Device profile present |
| evidence_sufficiency | PASS | G42 upstream gate |
| retrieval_domain | PASS | Upstream gate |
| retrieval_completeness | PASS | 3/3 databases searched |
| screening_pool | PASS | Upstream gate |
| fulltext_basis | PASS | Full-text check |
| SOTA | PASS | Benchmark table populated |
| **claim_evidence** | **BLOCKED** | C-04 has marketing language; requires human review |
| BR | PASS | Benefit-risk |
| alignment | PASS | GSPR/RMF alignment |
| endpoint_framework_locked | PASS | Endpoints locked |
| clinical_data_consolidated | PASS | Clinical data present |
| eu_market_status_set | PASS | Status: not_approved |

**Key finding:** G46 correctly BLOCKED on `claim_evidence` due to C-04's marketing language ("revolutionary", "guarantees perfect"). This is correct behavior — the Writer should not be released until the marketing claim is resolved. **0 silent PASS conditions.**

---

## 5. Conclusion

**Dry-run: PASS.** All BIGDP2026.6 code paths executed successfully. G46 correctly blocks marketing-overreach claims. All 3 ledgers populated with non-trivial content. Package validation passes.
